FDA Clocks In Extra Time for IMDELLTRA Patent Protection
Published Date: 7/14/2025
Notice
Summary
The FDA has officially set the review period for IMDELLTRA, a human biological product, so its patent can be extended. This helps the company get extra time to protect their invention before generic versions can appear. If you’re in the business of making or selling this product, this timing update is key for planning and profits.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Patent Extension Window for IMDELLTRA
If you make or sell IMDELLTRA, the FDA has set the product's regulatory review period so the company can apply to extend a patent that claims this human biological product. That extension gives the company extra time to protect the product before generic versions can appear, which matters for business planning and profits.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in